ABSTRACT
INTRODUCTION
Sarcoidosis occurs worldwide, in both sexes and in all races and ages, but it is well known that ethnicity is strongly associated with the significant heterogeneity seen in disease presentation and severity. Extrapulmonary manifestations occur more frequently in certain populations: chronic uveitis in African-Americans, lupus pernio in Puerto Ricans and erythema nodosum in Europeans. The ACCESS Study group found that African-Americans had more frequent involvement of the eye, liver, bone marrow, extrathoracic lymph nodes and skin (other than erythema nodosum), and that abnormal calcium metabolism was more common in European subjects. 1 There are limited data on the frequency of end-stage pulmonary fibrosis in sarcoidosis; in the ACCESS Study, 5.4% of the patients had evidence of pulmonary fibrosis on chest radiograph. 2 In New Zealand, the prevalence of sarcoidosis has been reported as 23 of 100 000 for males and 27.8 of 100 000 for females. 3 We have observed that our Maori and Pacific Islander (PI) patients with sarcoidosis have a disease severity and progression intermediate to that described in Europeans and American populations of African descent. Whilst New Zealand European patients appear to share similar characteristics to other European populations, 4 it was our impression that Maori and PI patients with sarcoidosis are more likely to present with extra-thoracic manifestations and less 
SUMMARY AT A GLANCE
This is the first study of clinical features of sarcoidosis in people of Polynesian ancestry; Maori and Pacific Islanders. This ethnic group presents with less pulmonary and more extra-pulmonary disease, but requirement for treatment is the same.
likely to have pulmonary fibrosis. That would be in accord with our previous report of a low prevalence of idiopathic pulmonary fibrosis (IPF) in Maori and PI. 5 The aim of this study was to compare the characteristics of sarcoidosis between New Zealand European subjects and those of Polynesian ancestry, Maori and PI.
METHODS
The medical records of 406 patients with sarcoidosis attending the interstitial lung disease (ILD) clinic at Green Lane Clinical Centre were reviewed. This clinic provides a service for the local Auckland population as well as complex sarcoidosis care for a small number of patients from other centres. Formal ethical approval was not required because of the purely observational nature of the study. Data pertaining to demographics, smoking status at presentation, chest X-ray (CXR) stage at presentation (according to Scadding classification), 6 baseline HRCT, organ systems ever involved, bronchoalveolar lavage (BAL) cytology and baseline physiology were collected. Where baseline HRCT was performed (n = 270), the presence of the following reported patterns was documented: hilar and mediastinal lymphadenopathy, ground glass opacification, nodules, reticular shadowing and dense opacification. Formal scoring of the patterns and extent of disease was not undertaken. Sarcoid organ involvement was defined as follows: pulmonary; evidence of parenchymal disease on CXR or HRCT, ocular; ophthalmologist diagnosis, skin; biopsy proven excluding erythema nodosum, spleen; palpable splenomegaly, neurologic; neurologist diagnosis, peripheral nodes; palpable lymphadenopathy and/or positive biopsy, cardiac; cardiologist diagnosis, hypercalcaemia; serum calcium >2.55 mmol/L, parotid; palpable parotid hypertrophy, erythema nodosum; clinical examination appearance. Ethnicity was self-determined. Data regarding specific therapy was not recorded but the need for treatment was recorded. Treatment was determined by the American Thoracic Society/European Respiratory Society/ World Association of Sarcoidosis and Other Granulomatous Disorders (ATS/ERS/WASOG) Statement on sarcoidosis. 7 Descriptive analysis was used to describe the cohort. Categorical values were compared using the chi-square statistic. Data were adjusted for history of current or ever-smoking. Analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
The population (207 females, mean age at presentation: 36) reflected the current New Zealand census data (2013) with only people of Indian ethnicity overrepresented (Table 1) . Maori and PI patients were more likely than European to be current or ex-smokers (58% vs 40%, P = 0.01).
There was no difference between the populations with respect to age at presentation, gender or family history of sarcoidosis. For the population as a whole and restricted by ethnicity, there was evidence of a unimodal age at presentation. There was a trend to late winter/spring peak presentation but this was not significant.
With respect to presentation lung parenchymal involvement, this was rare (14 patients; stages 2 and 3 CXR appearance) in Maori and PI patients who were more likely to present with hilar and mediastinal lymphadenopathy compared with Europeans (P = 0.005; Table 2 ). Maori and PI patients were more likely to have hilar and mediastinal node enlargement and less likely to have reported patterns of parenchymal lung involvement on HRCT (Table 3) , and significantly so in respect of ground glass shadowing, nodules and reticular shadowing. There were no differences in respect of peripheral blood counts or serum angiotensinconverting enzyme (ACE) levels at presentation nor was there any difference between the groups in respect of baseline lung function (Table 4) or need for treatment at any time during the illness. The only extra-thoracic manifestations in which there was a significant difference between ethnic groups were ocular and skin involvement, both occurring more frequently in Maori and PI (P = 0.0045, P = 0.03; Table 5 ), and erythema nodosum occurring more frequently in European patients (P = 0.0008; Table 5 ).
DISCUSSION
Sarcoidosis appears to occur with equal frequency in New Zealand European and Polynesian (Maori and PI) populations with perhaps a higher prevalence in those of Indian ethnicity. It is very rarely seen in New Zealand Asian populations. These data suggest that extra-thoracic manifestations are more likely in Maori/PI patients and that parenchymal lung disease as a consequence of sarcoidosis is less common in those of Polynesian ancestry. In particular, Maori/PI patients were more likely to have skin or ocular disease and there were no patients with cardiac sarcoidosis, noting the high prevalence in Japanese populations. 8 Anecdotally, Maori and PI patients can have very disfiguring lupus pernio with associated sino-nasal disease but information about mixed patterns of extrapulmonary involvement was not recorded. The computed tomography (CT) data, whilst retrospective and not formally scored, are congruent with the CXR staging and suggests that Maori and PI patients have less parenchymal disease compared with European patients. Significantly, the patterns of reticular shadowing and dense opacification, which represent the fibrotic process, were uncommon. Without formal scoring, we cannot present data on the extent or distribution of these patterns but the CT data taken together with the CXR staging suggests that Maori and PI patients are less likely to develop pulmonary fibrosis as a consequence of sarcoidosis. We have previously reported an observed low prevalence of IPF in Maori and PI patients, 5 acknowledging confounders such as lower overall life expectancy, but there is no evidence of a common aetiological pathway to pulmonary fibrosis in these disorders so the significance of that observation is not clear in respect of these sarcoidosis data.
Racial differences in the clinical phenotype of sarcoidosis are well recognized, and whilst there may be a socio-economic influence, the dominant cause is likely to be genetic. Erythema nodosum is well recognized as being more prevalent in European populations and rare in Japanese. Sarcoidosis occurs more frequently, and follows a worse disease course, in US African Americans 7,9 compared with their Caucasian counterparts. Polynesian people are thought to have shared genetic origins with Asian people, because of the migration of the Lapita people across from southern China and Taiwan to the Pacific Islands some 6000 years ago. However, we are unaware of any reports of Asian populations having less pulmonary and more extra-pulmonary disease in sarcoidosis. 10, 11 Many studies have identified haplotypes and molecular associations with, but not explanations for, the diverse clinical phenotypes observed in sarcoidosis and some of those are linked to ethnic differences. [12] [13] [14] The limitation of many of the genetic studies in sarcoidosis is that few studies with positive associations have been replicated, and even fewer have examined the functional effects of the genetic polymorphisms.
Maori and PIs living in New Zealand have a higher incidence of tuberculosis than people of European ancestry 15 and particular care is taken to exclude that as a cause of the granulomatous inflammation in these patients. Conversely, some patients have been empirically treated with anti-tuberculous medication and the diagnosis of sarcoidosis overlooked. These data emphasize the need to be cognizant of the diagnosis of sarcoidosis in Maori and PI patients when the classical pulmonary features are absent.
This study did not attempt to examine treatment responses by ethnicity as the retrospective nature of data collection precluded robust data for analysis, nor did the study examine socio-economic factors or occupation. There are considerable short comings in any retrospective cohort study and despite the large study sample the number of Maori and PI subjects is relatively small so safe conclusions cannot be drawn. However, these data do provide justification for further study.
In summary, this study confirms the clinical observation that Maori and PI patients with sarcoidosis are more likely to have extra-pulmonary disease and less likely to have severe pulmonary consequences, adding to our knowledge of the heterogeneity of the sarcoid phenotype between different ethnic groups.
